Risk of recurrence and bleeding in patients with cancer‐associated venous thromboembolism treated with rivaroxaban: A nationwide cohort study
Open Access
- 14 February 2019
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 8 (3) , 1044-1053
Abstract
Background: Rivaroxaban could be an attractive alternative to low molecular weight heparin for the treatment of cancer‐associated venous thromboembolism (VTE) but the safety and effectiveness remain unclear. We examined risk of recurrent VTE and major bleeding associated with rivaroxaban treatment of cancer‐associated VTE.Methods: Through linkage of nationwide Danish registries, we identified all adults with cancer‐associated VTE initiating treatment with rivaroxaban, 2012‐2017. We estimated rates and absolute risk of the primary outcome of recurrent VTE and major bleeding; all‐cause mortality was studied as a secondary outcome.Results: We identified 8901 patients with cancer‐associated VTE of whom 476 (5.3%) redeemed a prescription for rivaroxaban within 30 days of VTE diagnosis (mean age 71.5 years, 41% females, 57% with pulmonary embolism). Median time from cancer diagnosis to rivaroxaban prescription was 31 days (interquartile range 12‐73 days). Most frequent cancers were gastrointestinal (26.1%), genitourinary (23.3%), and hematological cancer (12.6%). Few had distant metastases (7.1%). At 6 months, recurrent VTE occurred in 6.1% (15.1 events per 100 person‐years) with the highest absolute risks for genitourinary cancer (8.1%), gastrointestinal cancer (7.3%), and breast cancer (6.5%). Major bleeding occurred in 1.9% (5.3 events per 100 person‐years), in particular, in genitourinary cancer (4.5%) and lung cancer (4.2%). Eighty deaths (17.8%) occurred during follow up.Conclusion: In this clinical practice setting, rivaroxaban was rarely used for cancer‐associated VTE. However, among those who received rivaroxaban, the treatment appeared safe and effective with rates comparable to previous studies of selected populations.Keywords
Funding Information
- Bayer AG
This publication has 39 references indexed in Scilit:
- Direct Oral Anticoagulants in Patients With VTE and CancerChest, 2015
- The Danish Civil Registration System as a tool in epidemiologyEuropean Journal of Epidemiology, 2014
- Epidemiology of cancer-associated venous thrombosisBlood, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer2011
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with cautionJournal of Clinical Epidemiology, 2010
- Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with CancerNew England Journal of Medicine, 2003
- Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisBlood, 2002
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987